Your browser doesn't support javascript.
loading
Medulloblastoma and Cowden syndrome: Further evidence of an association.
Albrecht, Steffen; Miedzybrodzki, Barbara; Palma, Laura; Nguyen, Van Hung; Dudley, Roy W R; Pietsch, Torsten; Goschzik, Tobias; Jabado, Nada; Goudie, Catherine; Foulkes, William D.
Afiliación
  • Albrecht S; Department of Pathology, McGill University, Montreal, QC Canada.
  • Miedzybrodzki B; Division of Dermatology, Department of Pediatrics, McGill University Health Centre, Montreal Children's Hospital, Montreal, QC Canada.
  • Palma L; Department of Human Genetics, McGill University, Montreal, QC Canada.
  • Nguyen VH; Division of Medical Genetics, Department of Specialized Medicine, McGill University Health Centre, Montreal, QC Canada.
  • Dudley RWR; Department of Pathology, McGill University, Montreal, QC Canada.
  • Pietsch T; Division of Neurosurgery, Department of Pediatric Surgery, Montreal Children's Hospital, McGill University Health Centre, Montreal, QC Canada.
  • Goschzik T; Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Bonn Germany.
  • Jabado N; Department of Neuropathology, DGNN Brain Tumor Reference Center, University of Bonn Medical Center, Bonn Germany.
  • Goudie C; Department of Human Genetics, McGill University, Montreal, QC Canada.
  • Foulkes WD; Department of Pediatrics, McGill University, Montreal, QC Canada.
Free Neuropathol ; 32022 Jan.
Article en En | MEDLINE | ID: mdl-37284158
Cowden syndrome (CS) is an autosomal dominant hamartoma and tumor predisposition syndrome caused by heterozygous pathogenic germline variants in PTEN in most affected individuals. Major features include macrocrania, multiple facial tricholemmomas, acral and oral keratoses and papillomas, as well as mammary, non-medullary thyroid, renal, and endometrial carcinomas. Lhermitte-Duclos disease (LDD), or dysplastic gangliocytoma of the cerebellum, is the typical brain tumor associated with CS; the lifetime risk for LDD in CS patients has been estimated to be as high as 30%. In contrast, medulloblastoma is much rarer in CS, with only 4 reported cases in the literature. We report a 5th such patient. All 5 patients were diagnosed between 1 and 2 years of age and not all showed the pathognomonic clinical stigmata of CS at the time of their medulloblastoma diagnosis. Where detailed information was available, the medulloblastoma was of the SHH-subtype, in keeping with the observation that in sporadic medulloblastomas, PTEN-alterations are usually encountered in the SHH-subtype. Medulloblastomas can be associated with several tumor-predisposition syndromes and of the 4 medulloblastoma subtypes, SHH-medulloblastomas in children have the highest prevalence of predisposing germline variants (approx. 40%). CS should be added to the list of SHH-medulloblastoma-associated syndromes. Germline analysis of PTEN should be performed in infants with SHH-medulloblastomas, regardless of their clinical phenotype, especially if they do not carry pathogenic germline variants in PTEN or PTEN, the most commonly altered predisposing genes in this age-group. In addition, these cases show that CS has a biphasic brain tumor distribution, both in regards to the age of onset and the tumor type: a small number of CS patients develop a medulloblastoma in infancy while many more develop LDD in adulthood.
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Free Neuropathol Año: 2022 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Free Neuropathol Año: 2022 Tipo del documento: Article